Your session is about to expire
← Back to Search
batiraxcept for Pancreatic Adenocarcinoma
Study Summary
This trial is testing a new cancer drug (AVB-S6-500) to see if it is safe and effective when used with two other drugs (nab-paclitaxel and gemcitabine) to treat pancreatic cancer. The trial has two parts: in the first part, all patients receive AVB-S6-500, nab-paclitaxel, and gemcitabine; in the second part, patients are randomly assigned to receive either AVB-S6-500, nab-paclitaxel, and gemcitabine or nab-paclitaxel and gemcitabine
- Pancreatic Adenocarcinoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Phase 1b: batiraxcept+ nab-paclitaxel and gemcitabine
- Group 2: Phase 2: batiraxcept+ nab-paclitaxel and gemcitabine
- Group 3: Phase 2: nab-paclitaxel and gemcitabine alone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the cap for enrollees in this clinical research?
"This trial is seeking 80 suitable patients from two locations - the Perlmutter Cancer Center at NYU Langone Health in New york, and Oregon Health and Science University in Portland. Those meeting inclusion criteria are welcome to join this clinical investigation."
What indications is batiraxcept most frequently employed to address?
"Batiraxcept is a medication frequently prescribed to manage the growth of secondary tumours and conditions such as locally advanced non-small cell lung cancer, metastatic bladder carcinoma, and urinary tract disorders."
What concurrent investigations have been conducted on batiraxcept?
"Currently, 1112 clinical trials are exploring the effects of batiraxcept with 321 studies in their last phase. The greatest concentration of these experiments is located in Shanghai, though there are a total of 59388 sites worldwide running this research."
Are there still available slots for participants in this clinical research study?
"Affirmative. According to clinicaltrials.gov, this investigation is in the process of recruitment which commenced on July 28th 2021; with updates provided as recently as February 21st 2022. The research aims to enrol 80 patients from 18 distinct medical centres."
What are the paramount aims of this research project?
"This 12-month clinical trial will survey the anti-tumor activity of AVB-S6-500 combined with nab-paclitaxel and gemcitabine. Secondary objectives involve gauging overall survival, duration of response (DOR), along with pharmacokinetics such as apparent terminal half life (t1/2)."
Share this study with friends
Copy Link
Messenger